| Dr Harry Allen, MD | |
|
110 Kingsley Ln, Norfolk, VA 23505-4614 | |
| (757) 889-5422 | |
| Not Available |
| Full Name | Dr Harry Allen |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 45 Years |
| Location | 110 Kingsley Ln, Norfolk, Virginia |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295796209 | NPI | - | NPPES |
| 7240414 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0101035627 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Virginia Beach General Hospital | Virginia beach, VA | Hospital |
| Sentara Obici Hospital | Suffolk, VA | Hospital |
| Sentara Princess Anne Hospital | Virginia beach, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hampton Roads Radiology Associates, Pc | 4880688506 | 39 |
News Archive
A new research report appearing in the March 2012 issue of the journal Genetics shows why the development of a cure and new treatments for HIV has been so difficult. In the report, an Australian scientist explains how he used computer simulations to discover that a population starting from a single human immunodeficiency virus can evolve fast enough to escape immune defenses.
Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons' has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.
› Verified 2 days ago
| Entity Name | Hampton Roads Radiology Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174533624 PECOS PAC ID: 4880688506 Enrollment ID: O20041123000788 |
News Archive
A new research report appearing in the March 2012 issue of the journal Genetics shows why the development of a cure and new treatments for HIV has been so difficult. In the report, an Australian scientist explains how he used computer simulations to discover that a population starting from a single human immunodeficiency virus can evolve fast enough to escape immune defenses.
Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons' has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Harry Allen, MD Po Box 844555, Boston, MA 02284-4555 Ph: (540) 891-8730 | Dr Harry Allen, MD 110 Kingsley Ln, Norfolk, VA 23505-4614 Ph: (757) 889-5422 |
News Archive
A new research report appearing in the March 2012 issue of the journal Genetics shows why the development of a cure and new treatments for HIV has been so difficult. In the report, an Australian scientist explains how he used computer simulations to discover that a population starting from a single human immunodeficiency virus can evolve fast enough to escape immune defenses.
Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons' has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.
› Verified 2 days ago
Dr. Kevin Halista, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 110 Kingsley Ln, Suite 305, Norfolk, VA 23505 Phone: 804-262-6900 | |
Dr. Julie Anne Krumreich, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 218 E 42nd St, Norfolk, VA 23504 Phone: 757-963-6713 | |
Norbertina L Banson, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 835 Glenrock Rd, Ste 100a, Norfolk, VA 23502 Phone: 757-252-3370 Fax: 757-252-3225 | |
Mark Cockerill, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 150 Kingsley Ln, Norfolk, VA 23505 Phone: 757-889-5422 Fax: 757-889-5450 | |
Dr. Marc L Pessar, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 850 Kempsville Rd, Norfolk, VA 23502 Phone: 757-466-5910 Fax: 757-466-5748 | |
Dr. Suraj Jaisinghani, MD Radiology Medicare: Medicare Enrolled Practice Location: 600 Gresham Dr, Norfolk, VA 23507 Phone: 585-922-2932 | |
Todd Matthew Berry, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 110 Kingsley Ln Ste 305, Norfolk, VA 23505 Phone: 757-889-5422 Fax: 757-889-5450 |